Condition: Non Small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Pancreas Adenocarcinoma · Sponsor: Zumutor Biologics Inc.
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
This description comes directly from the study's public registry record.
Maloy Ghosh, PhD · +91 80 69121400 · maloy.ghosh@zumutor.com
Jyotsna Fuloria, MD · 5046062594 · jyotsna.fuloria@fuloriaresearch.org
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| NEXT Oncology | Austin, TX 78758, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06451497